- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT06384586
Investigation of Dietary Supplement Liquid Shot Products on Mental Energy, Cognition (Acuity),and Mood
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
New Jersey
-
Iselin, New Jersey, United States, 08330
- Schlesinger Group New Jersey
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
Accepts Healthy Volunteers
Description
Inclusion Criteria:
MAIN INCLUSION CRITERIA:
- Participants must be willing to abstain from alcohol, caffeine and exercise starting from the night before each session.
- Participants that, on average, consume between 200 and 500 mgs of caffeine per day.
- Participants that are in good physical and mental health.
- Participants that are willing to come in-person and be within less than 6 feet of study staff for a short period of time.
- Participants that are able to provide written informed consent to participate in the study and will have agreed to abide by the study restrictions, requirements and protocol.
- Participants must, in the opinion of the Principal Investigator (or designee), demonstrate the ability to comprehend the informed consent form (ICF), be able to communicate well with the Investigator, understand and comply with the requirements of the study, and be judged suitable for the study.
- Participants must be available to complete the study.
- Participants must be willing to consume a normal-sized meal (participant responsible for obtaining or preparing the meal) at least one hour prior to the start of the study session and then fast from food and beverage consumption (except water), for one hour prior to each research session.
Exclusion Criteria:
- Participants that are not US citizens or are residents of California.
- Participants that have a medical condition, including but not limited to heartbeat/rhythm irregularities, past heart attacks, been diagnosed with heart disease, seizure disorder, liver condition, blood clotting disorder, endocrine-related medical diagnosis (such as diabetes, thyroid, etc.), serious health condition (i.e. cancer, etc.), blindness, gastrointestinal sensitivity/condition, depression, insomnia, anxiety, hypertension, PKU (Phenylketonuria), Celiac disease or deafness. If a participant has any other medical condition or metabolic condition that prevents them from being able to fast for one hour, they will not be allowed to participate in this study.
- Participants that have a loss of taste or smell or are currently suffering from a virus/infection that affects their ability to taste or smell.
- Participants that are left-handed, have dyscalculia, have paralysis which effects the upper body, or are color-blind, as this could impact their ability to complete the cognitive tasks.
- Participants that use recreational drugs or that are currently taking medication (except for a contraceptive), or other drugs including non-prescription (over the counter) medications, pseudoephedrine, non-prescription painkillers such as paracetamol (acetaminophen), ibuprofen or aspirin.
- Participants that are taking green tea extract or any diet medications, appetite suppressors or supplements (including, but not limited to, fitness supplements containing green tea extract and caffeine, and workout supplements that are intended to assist with weight loss (such as phentermine)).
- Participants that are pregnant, breastfeeding (or pumping/expressing) or intend to become pregnant in the next six months.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Basic Science
- Allocation: Randomized
- Interventional Model: Crossover Assignment
- Masking: Triple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Placebo Comparator: Placebo
Placebo 60 ml Shot, matched in volume, taste and colour and did not contain any active ingredients.
1 shot to be consumed per session
|
60ml shot served in an amber bottle and consumed after 40 minutes of baseline assessments
60ml shot served in an amber bottle and consumed after 40 minutes of baseline assessments
|
|
Experimental: Functional Energy shot
60ml functional energy shot contained a proprietary blend of caffeine, ginseng, vitamins and taurine. 1 shot to be consumed per session
|
60ml shot served in an amber bottle and consumed after 40 minutes of baseline assessments
60ml shot served in an amber bottle and consumed after 40 minutes of baseline assessments
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Mental energy via Cognitive Demand Battery (CDB) Performance Index; for the functional energy shot versus placebo shot.
Time Frame: Change from baseline to 120 min post- shot consumption
|
CDB performance index score is a comprised averaged Z scores for the principal performance measure for each of the three tasks: Rapid Visual Information Processing (RVIP) % accuracy, Serial 3s total number correct, Serial 7s total number correct.
A higher score signifies performance improvement.
Objective tests within Computerised Mental Performance Assessment framework tasks (COMPASS)
|
Change from baseline to 120 min post- shot consumption
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Mental energy via Cognitive Demand Battery (CDB) Accuracy score for the functional energy shot versus placebo shot.
Time Frame: Change from baseline to 120 min post- shot consumption
|
CDB accuracy score is a comprised averaged Z scores for the principal measures of accuracy of performance for the three tasks: Rapid Visual Information Processing (RVIP) % accuracy; Serial 3s % errors; Serial 7s % errors (the latter two were inverted so that a higher Z score related to better accuracy). A higher score signifies performance improvement. Objective tests within Computerised Mental Performance Assessment framework tasks (COMPASS) |
Change from baseline to 120 min post- shot consumption
|
|
Change in performance on Corsi blocks task for functional energy shot versus placebo
Time Frame: Change from baseline to 120 min post- shot consumption
|
Objective tests within Computerised Mental Performance Assessment framework tasks (COMPASS)
|
Change from baseline to 120 min post- shot consumption
|
|
Change in performance on Rapid Visual Information Processing (RVIP) for functional energy shot versus placebo
Time Frame: Change from baseline to 120 min post- shot consumption
|
Objective tests within Computerised Mental Performance Assessment framework tasks (COMPASS)
|
Change from baseline to 120 min post- shot consumption
|
|
Change in performance on Numeric working memory for functional energy shot versus placebo
Time Frame: Change from baseline to 120 min post- shot consumption
|
Objective tests within Computerised Mental Performance Assessment framework tasks (COMPASS)
|
Change from baseline to 120 min post- shot consumption
|
|
Change in performance on Serial subtraction task for functional energy shot versus placebo
Time Frame: Change from baseline to 120 min post- shot consumption
|
Objective tests within Computerised Mental Performance Assessment framework tasks (COMPASS)
|
Change from baseline to 120 min post- shot consumption
|
|
Change in Mood via Visual Analogue Scales (VAS) during Cognitive Demand Battery (CDB), for functional energy shot versus placebo
Time Frame: Change from baseline to 120 min post- shot consumption
|
0-100 mm subjective rating scale from none to strongest feelings, within Computerised Mental Performance Assessment framework tasks (COMPASS) for mental fatigue, alert, sociable, simulated, jittery, physical energy.
The minimum score is 0 and the maximum score is 100.
|
Change from baseline to 120 min post- shot consumption
|
|
Change in physiological state via Profile Of Mood States (POMS) during Cognitive Demand Battery (CDB), for functional energy shot versus placebo
Time Frame: Change from baseline to 120 min post- shot consumption
|
a 37-item inventory, the individual item scores of which are collapsed into six dimensions of mood: anger/hostility, confusion/bewilderment, depression/dejection, fatigue/inertia, tension/anxiety, and vigour/activity.
|
Change from baseline to 120 min post- shot consumption
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Michelle M Niedziela, PhD, HCD Research
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- CD J8855
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Mental Fatigue
-
Bakulev Scientific Center of Cardiovascular SurgeryFoundation for the Support of Physical Culture and Sports BECOME A CHAMPION; Autonomous Non-Profit organization of additional education sports school BECOME A CHAMPIONRecruitingEfficacy, Self | Fatigue, Mental | Fatigue; Muscle, Heart | Fatigue; CombatRussian Federation
-
University of Southern MississippiEnrolling by invitationFatigue, Mental | Fatigue; Muscle, HeartUnited States
-
Universita di VeronaUniversity of Southern CaliforniaCompletedDiet, Healthy | Fasting | Fatigue, Mental | Fatigue; Muscle, HeartItaly
-
Supplement Formulators, Inc.Completed
-
PepsiCo Global R&DCompletedMotivation | Mood | Cognitive Performance | Fatigue, Mental | AlertnessUnited States
-
University GhentCompletedMental Fatigue | Muscle Fatigue | Event-related PotentialsBelgium
-
Vedic Lifesciences Pvt. Ltd.CompletedAlert Fatigue, Health PersonnelIndia
-
Guizhou Medical UniversityThe Affiliated Hospital Of Guizhou Medical UniversityEnrolling by invitationAlert Fatigue, Health PersonnelChina
-
University of GeorgiaThe Hershey CompanyCompleted
-
Eskisehir Osmangazi UniversityRecruitingStress Perception, Psychological Resilience, Compassion FatigueTurkey
Clinical Trials on Placebo shot
-
Bangor UniversityCompleted
-
The Water Street CollectiveBritish American Tobacco (Investments) Limited; HCD ResearchCompletedStress | Mood | AlertnessUnited Kingdom
-
PepsiCo Global R&DCompleted
-
University of ManitobaCompleted
-
David Travis ThomasCompletedMucositisUnited States
-
Jiangsu Province Centers for Disease Control and...Completed
-
Penn State UniversityCompleted
-
University of DelawareCompletedEndothelial Dysfunction | Kidney Disease, ChronicUnited States
-
Newcastle UniversityUniversity of Nottingham; Liverpool John Moores University; University of the... and other collaboratorsCompletedBlood PressureUnited Kingdom
-
Shanghai Institute Of Biological ProductsCompleted